"Dinoprostone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa.
| Descriptor ID |
D015232
|
| MeSH Number(s) |
D10.251.355.255.550.250.200 D23.469.050.175.725.250.200
|
| Concept/Terms |
Dinoprostone- Dinoprostone
- PGE2 alpha
- alpha, PGE2
- Prostaglandin E2alpha
- E2alpha, Prostaglandin
- Prostaglandin E2
- E2, Prostaglandin
- Prostaglandin E2 alpha
- E2 alpha, Prostaglandin
- alpha, Prostaglandin E2
- PGE2
- PGE2alpha
|
Below are MeSH descriptors whose meaning is more general than "Dinoprostone".
Below are MeSH descriptors whose meaning is more specific than "Dinoprostone".
This graph shows the total number of publications written about "Dinoprostone" by people in this website by year, and whether "Dinoprostone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1994 | 2 | 1 | 3 |
| 1996 | 1 | 1 | 2 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 4 | 2 | 6 |
| 2004 | 3 | 3 | 6 |
| 2005 | 4 | 5 | 9 |
| 2006 | 4 | 3 | 7 |
| 2009 | 2 | 4 | 6 |
| 2010 | 3 | 1 | 4 |
| 2011 | 2 | 1 | 3 |
| 2012 | 2 | 3 | 5 |
| 2013 | 5 | 2 | 7 |
| 2014 | 1 | 4 | 5 |
| 2015 | 3 | 1 | 4 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dinoprostone" by people in Profiles.
-
Wilson DJ, DuBois RN. Role of Prostaglandin E2 in the Progression of Gastrointestinal Cancer. Cancer Prev Res (Phila). 2022 06 02; 15(6):355-363.
-
Wei J, Zhang J, Wang D, Cen B, Lang JD, DuBois RN. The COX-2-PGE2 Pathway Promotes Tumor Evasion in Colorectal Adenomas. Cancer Prev Res (Phila). 2022 05 03; 15(5):285-296.
-
Wang D, Cabalag CS, Clemons NJ, DuBois RN. Cyclooxygenases and Prostaglandins in Tumor Immunology and Microenvironment of Gastrointestinal Cancer. Gastroenterology. 2021 12; 161(6):1813-1829.
-
Cen B, Lang JD, Du Y, Wei J, Xiong Y, Bradley N, Wang D, DuBois RN. Prostaglandin E2 Induces miR675-5p to Promote Colorectal Tumor Metastasis via Modulation of p53 Expression. Gastroenterology. 2020 03; 158(4):971-984.e10.
-
Madaio MP, Czikora I, Kvirkvelia N, McMenamin M, Yue Q, Liu T, Toque HA, Sridhar S, Covington K, Alaisami R, O'Connor PM, Caldwell RW, Chen JK, Clauss M, Brands MW, Eaton DC, Romero MJ, Lucas R. The TNF-derived TIP peptide activates the epithelial sodium channel and ameliorates experimental nephrotoxic serum nephritis. Kidney Int. 2019 06; 95(6):1359-1372.
-
Wang D, DuBois RN. Role of prostanoids in gastrointestinal cancer. J Clin Invest. 2018 07 02; 128(7):2732-2742.
-
Ikari J, Nelson AJ, Obaid J, Giron-Martinez A, Ikari K, Makino F, Iwasawa S, Gunji Y, Farid M, Wang X, Basma H, Demeo D, Feghali-Bostwick C, Holz O, Rabe K, Liu X, Rennard SI. Reduced microRNA-503 expression augments lung fibroblast VEGF production in chronic obstructive pulmonary disease. PLoS One. 2017; 12(9):e0184039.
-
Kimmel DW, Rogers LM, Aronoff DM, Cliffel DE. Prostaglandin E2 Regulation of Macrophage Innate Immunity. Chem Res Toxicol. 2016 Jan 19; 29(1):19-25.
-
Kvirkvelia N, McMenamin M, Gutierrez VI, Lasareishvili B, Madaio MP. Human anti-a3(IV)NC1 antibody drug conjugates target glomeruli to resolve nephritis. Am J Physiol Renal Physiol. 2015 Oct 15; 309(8):F680-4.
-
Wang D, Fu L, Sun H, Guo L, DuBois RN. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice. Gastroenterology. 2015 Dec; 149(7):1884-1895.e4.